Researchers at the Institute for Research in Biomedicine (IRB) in Barcelona set out to study estrogen-positive (ER+) breast tumors that feature long periods of asymptomatic latency. This type accounts for 80 percent of breast cancer cases.
The Barcelona team identified a protein kinase called MSK1 as the primary regulator of dormant metastases. After examining clinical samples from patients, the researchers determined that ER+ breast cancer tumors that don’t express MSK1 tend to suffer earlier relapse, while those that do express MSK1 experience later metastases.
Breakthrough in Breast Cancer Treatment
Head researcher Roger Gormis explained that little was previously known about why breast cancer metastasis time varies from one patient to another. Study results also showed that suppressing MSK1 causes faster-growing cancer cells that have a greater chance of metastasizing.
Benefits of the study are two-fold:
– Doctors may be better able to identify patients who are more likely to relapse and adjust treatment protocol.
– Scientists may be able to develop a treatment that mimics the role of MSK1, thereby keeping metastasis dormant for as long as possible.
Effective Late-Stage Cancer Treatment at Issels®
Our non-toxic, personally tailored immunotherapy programs have effectively treated patients with late-stage and therapy resistant cancer of all forms, including breast, lung and colorectal. Contact us to learn more about why Issels® is the leader in state-of-the-art immunotherapy treatments.
Many women do not trust the health care system and will often forgo radiation and drug therapy after breast cancer surgery. That is according to a survey of 2,700 breast cancer patients by researchers at Johns Hopkins University. Lead author of the survey, Lorraine Dean, said over 30 percent skip treatments that are intended to kill any cancer cells that remain after surgery.
Contact Issels® for information on how combining conventional treatments with immunotherapy cancer treatment reduces the likelihood of relapse.
Doctor-patient trust is crucial
Cancer is a devastating disease and it is understandable that patients experience feelings of helplessness. It’s not just women with breast cancer who are losing trust in doctors and the health care system, it’s the general public as well. People often feel that doctors put their own financial interest ahead of patient care. When patients feel their doctors don’t listen to them or take their concerns seriously, trust begins to erode.
For the best possible outcome, it is necessary that doctors and patients have a strong bond of trust. Patients should feel comfortable being fully honest with health care providers and the doctors should always remember that a patient’s trust in them is a vital and necessary component of proper medical care. Each person’s cancer is unique and treatment should be based on the specific needs of each patient.
Personalized cancer treatment
At Issels®, we have been practicing individualized treatment for more than 60 years. We want you to make informed decisions about your cancer treatment options. Contact us today for more information on our autologous (from the patient’s own blood) non-toxic cancer treatment protocols.
One of the concerns with traditional cancer treatment is the range and severity of potential side effects that may occur. Based on the results of a recent study, patients with advanced breast cancer who are treated with a certain combination of drugs are at greater risk for serious side effects.
Fighting Cancer on Two Fronts
Some breast cancers are classified as “hormone receptor-positive.” Signals from hormones such as estrogen and progesterone reach receptors in the cancer cells, triggering further growth. Patients are commonly treated with a receptor blocker such as tamoxifen in conjunction with drugs that specifically target molecules involved in cancer cell development.
Previous research indicated that this combination therapy enabled patients to live longer without progression of the tumors. The missing piece of the puzzle was the extent to which treatment could cause side effects.
Evaluating Side Effects of Combination Therapies
A study conducted by an international research team found that patients with combination therapy were more susceptible to side effects such as fatigue, diarrhea and hyperglycemia. The degree of risk varied based on the particular drugs involved.
Scientists plan to use these results to design courses of treatment that are less likely to produce side effects. In the meantime, since these therapies do have benefits, doctors will have more information to use in prescribing and managing combination drug treatments.
Issels® Leads the Way with Non-Toxic Cancer Treatment
Personalized cancer treatment at Issels® uses a patient’s own immune cells, reducing the risk of of debilitating side effects. Contact us to learn more about our cancer vaccines and other innovative treatment programs.
PARP inhibitors make up a new class of cancer drugs that have been used primarily in a narrow application for women with ovarian and related forms of cancer. As presented at the European Society of Medical Oncology (ESMO) in Madrid last September, recent trial results open up possibilities of other uses.
The ARIEL-3 trial, sponsored by Clovis Oncology, involved 564 patients who received randomized doses of a placebo or Rubraca, a PARP inhibitor manufactured by Clovis. Rubraca was found to help women who had ovarian cancer both with and without BRCA mutations.
While Rubraca’s greatest effectiveness was in cases involving BRCA mutations, it also had a positive effect on some with other markers of impaired DNA repair. This condition is referred to as genomic scarring or BRCA-ness, related to a deficiency in homologous recombination repair (HRD).
Future Uses of PARP Inhibitors
Rubraca is currently approved in the U.S. for treatment of advanced BRCA-positive ovarian cancer. Based on the trial results, Clovis has applied for FDA approval of broader applications of Rubraca, including maintenance treatment. Researchers are hopeful that benefits will eventually extend to breast, pancreatic and prostate cancer.
Gene-Targeted Cancer Treatment Programs at Issels®
Gene-targeted therapies focus on blocking replication and growth of cancer cells, reducing risk to healthy cells. Contact us to learn more about cancer vaccines and other non-toxic cancer treatment programs at Issels®.
Actress and singer Olivia Newton-John has campaigned to raise awareness of cancer research since she began fighting the disease in 1992. In May she made the sad announcement that her breast cancer had returned and spread to her lower spine.
The Prognosis for Metastatic Breast Cancer
Newton-John’s breast cancer is metastatic, also known as Stage IV, which refers to cancer that begins in one area of the body and spreads to other organs or tissues. It was discovered when the singer postponed a concert tour due to lower back pain that was originally thought to be sciatica.
Family and friends remain positive, and Newton-John herself plans to resume touring in August. While metastatic breast cancer is a serious issue, doctors say that Newton-John and other women with this diagnosis have reason for optimism.
Five-Year Survival by the Numbers
A recent study published in Cancer Epidemiology, Biomarkers & Prevention discovered that the five-year survival rate for women with metastatic breast cancer had reached 36 percent during the last 10 years. That number is double the five-year survival rate for women diagnosed in the early 1990s.
According to Dr. Sagar Sardesai of the Ohio State University Comprehensive Cancer Center, the healthcare community has begun thinking of metastatic breast cancer as a chronic disease. Physicians are working with patients cancer treatment programs that relieve symptoms and improve their quality of life.
The researchers began by collecting blood and tissue samples from several men who had been diagnosed with breast cancer. These samples were then used for gene sequencing to identify mutations that could be causing the disease.
As a result, the scientists were able to identify mutations in the BRCA2 gene that triggered the cancer growth. In addition, the study found that lifestyle and reproductive factors such as hormonal therapy and alcohol consumption can also increase risk.
Differences between Male and Female Breast Cancer
The lumps (or primaries) associated with breast cancer are generally smaller in men than in women, making early detection difficult.
BRCA2 mutation carriers are found in lymph nodes, so men don’t experience the pain that would make them seek medical care.
Genomic Testing Personalizes Immunotherapy for Cancer
Each patient is different, so immunotherapy for cancer at Issels® uses genomic and other specialized testing to create the optimum course of treatment. Contact us today to learn more about our non-toxic integrative programs such as cancer vaccines and NK cells.